Von Willebrand factor is a multimeric glycoprotein that plays an essential role in platelet-rich thrombi formation under high shear stress. The heterogeneity of Von Willebrand disease (vWD) illustrates the complex physiology of this protein. For women, menstrual patterns and heavy menstrual bleeding are the most frequent disorders within the inherited bleeding disorders population. Pelvic pain due to recurrent hemorrhagic ovarian cyst does not appear to have a higher frequency in the vWD population. Though, it can be a source of impaired quality of life and many invasive procedures. In this report, we will describe the management of a recurrent ovarian cyst and show the importance of medical/conservative treatment without loaning to surgery.
Cite this paper
Nafidi, M. , Khald, A. , Aboulfalah, A. and Soummani, A. (2022). Recurrent Cyst within Willebrand Disease: Place of Surgery?. Open Access Library Journal, 9, e8731. doi: http://dx.doi.org/10.4236/oalib.1108731.
Werner, E.J., Broxson, E.H., Tucker, E.L., Giroux, D.S., Shults, J. and Abshire, T.C. (1993) Prevalence of von Willebrand Disease in Children: A Multiethnic Study. The Journal of Pediatrics, 123, 893-898. https://doi.org/10.1016/S0022-3476(05)80384-1
Bowen, D.J. and Collins, P.W. (2004) An Amino Acid Polymorphism in von Willebrand Factor Correlates with Increased Susceptibility to Proteolysis by ADAMTS13. Blood, 103, 941-947. https://doi.org/10.1182/blood-2003-05-1505
Castaman, G., Goodeve, A. and Eikenboom, J. (2013) Principles of Care for the Diagnosis and Treatment of von Willebrand Disease. Haematologica, 98, 667-674.
Kadir, R.A., Economides, D.L., Sabin, C.A., Owens, D. and Lee, C.A. (1999) Variations in Coagulation Factors in Women: Effects of Age, Ethnicity, Menstrual Cycle and Combined Oral Contraceptive. Thrombosis and Haemostasis, 82, 1456-1461.
Miller, C.H., Dilley, A.B., Drews, C., Richardson, L. and Evatt, B. (2002) Changes in von Willebrand Factor and Factor VIII Levels during the Menstrual Cycle. Thrombosis and Haemostasis, 87, 1082-1083. https://doi.org/10.1055/s-0037-1613140
Sie, P., Caron, C., Azam, J., Goudemand, J., Grandjean, H., Boneu, B., et al. (2003) Reassessment of von Willebrand Factor (VWF), VWF Propeptide, Factor VIII: C and Plasminogen Activator Inhibitors 1 and 2 during Normal Pregnancy. British Journal of Haematology, 121, 897-903.
David, J.L., Gaspard, U.J., Gillain, D., Raskinet, R. and Lepot, M.R. (1990) Hemostasis Profile in Women Taking Low-Dose Oral Contraceptives. American Journal of Obstetrics & Gynecology, 163, 420-423.
Biggs, R. and Matthews, J.M. (1963) The Treatment of Haemorrhage in von Willebrand’s Disease and the Blood Level of Factor VIII (AHG). British Journal of Haematology, 9, 203-214. https://doi.org/10.1111/j.1365-2141.1963.tb05458.x
Phillips, M.D. and Santhouse, A. (1998) von Willebrand Disease: Recent Advances in Pathophysiology and Treatment. The American Journal of the Medical Sciences, 316, 77-86. https://doi.org/10.1016/S0002-9629(15)40382-9
Lasry, A., Gil, Y. and Balayla, J. (2020) Use of Tranexamic Acid for the Treatment of Mittelschmerz in a Patient with Type 1 von Willebrand Disease and Recurrent Hemorrhagic Cysts. Journal of Obstetrics and Gynaecology Canada, 42, 1385-1387.
Bottomley, C. and Bourne, T. (2009) Diagnosis and Management of Ovarian Cyst Accidents. Best Practice & Research Clinical Obstetrics & Gynaecology, 23, 711-724.